<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739765</url>
  </required_header>
  <id_info>
    <org_study_id>#5660, R01 MH079078</org_study_id>
    <secondary_id>R01MH079078</secondary_id>
    <nct_id>NCT00739765</nct_id>
  </id_info>
  <brief_title>Effectiveness of Three Different Psychotherapies for Chronic Post-Traumatic Stress Disorder</brief_title>
  <official_title>Psychotherapies for Chronic Post-Traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether interpersonal psychotherapy is as effective in treating
      post-traumatic stress disorder as the established therapies of prolonged exposure and
      relaxation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-traumatic stress disorder (PTSD) is caused by a traumatic experience often involving
      physical harm or the threat of harm or death. The emotional numbness and traumatic flashbacks
      symptomatic of PTSD interfere with everyday life for approximately 7.7 million adults.
      Besides prescription drug treatment, only exposure-based therapies, like prolonged exposure
      (PE) therapy, have been proved effective in treating PTSD. Interpersonal psychotherapy (IPT),
      which is not based on exposure, is effective in treating mood disorders, and pilot studies
      indicate it may also be effective in treating PTSD. IPT treats patients by helping them to
      improve their interpersonal functioning, as opposed to PE, which helps patients by guiding
      them to recreate traumatic memories in safe circumstances. This study will determine whether
      IPT is as effective as PE, the gold standard, in treating PTSD. Relaxation therapy, a
      commonly used control therapy for studies of PTSD, will be used for that purpose here.

      All participants will be screened for PTSD, with those meeting the criteria being randomly
      assigned to one of the following three treatment groups:

        -  Group 1 participants will receive IPT. They will meet weekly for fourteen 50-minute
           sessions focusing on interpersonal consequences of the trauma affecting them and their
           relationships with others.

        -  Group 2 participants will receive PE. They will meet for 10, unevenly spaced 90-minute
           sessions during which they will face the trauma responsible for their symptoms.

        -  Group 3 participants will receive relaxation therapy. They will meet for nine 90-minute
           sessions and one 30-minute session during which they will learn relaxation methods.

      All treatments will last 14 weeks, with assessments made by mental health professionals at
      screening, the midpoint of the study, the end of the study, and a 3-month follow-up. PTSD
      symptoms will be assessed through clinical interviews and self-report measures. In addition,
      participants will complete other interviews and tests that will examine a variety of factors
      relating to mental health, including comorbidity of other conditions, affect, social
      functioning, and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician-Administered PTSD Scale (CAPS)</measure>
    <time_frame>After 14 weeks of treatment</time_frame>
    <description>Continuous measure scale of PTSD symptoms severity. Generally considered state of the art. Range 0-136 (17 items each rated for frequency and for intensity, each on a 0-4 scale). Scores &gt;50 indicate at least moderately severe PTSD; scores &lt;20 were defined as remission. See Blake DD, Weathers FW, Nagy LM, et al: The development of a clinician-administered PTSD scale. J Trauma Stress 1995; 8:75-90; Weathers FW, Keane TM, Davidson JRT: Clinician-Administered PTSD Scale: a review of the first ten years of research. Depression and Anxiety 2001;13:132-156</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>After 14 weeks of treatment</time_frame>
    <description>Continuous scale to measure depressive symptom severity with a potential range from 0 to 74. Higher scores indicate more severe depressive symptoms. Scores &lt;8 are generally considered not depressed; 8-12 mildly depressed; 13-19 moderately depressed; 20 and greater, severely depressed. Reference: Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;25:56-62</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>1 Interpersonal Psychotherapy (IPT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive interpersonal psychotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Prolonged Exposure (PE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive prolonged exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Relaxation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive relaxation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Interpersonal Psychotherapy</intervention_name>
    <description>14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports</description>
    <arm_group_label>1 Interpersonal Psychotherapy (IPT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prolonged Exposure Therapy</intervention_name>
    <description>Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma</description>
    <arm_group_label>2 Prolonged Exposure (PE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relaxation Therapy</intervention_name>
    <description>Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD</description>
    <arm_group_label>3 Relaxation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria for
             primary, chronic PTSD

          -  At least moderately severe symptoms, defined by a minimum total (frequency plus
             severity) Clinician-Administered PTSD Scale score greater than 50

          -  Willing to undergo an independent clinical assessment and other ratings

        Exclusion Criteria:

          -  Diagnosis of schizophrenia, bipolar disorder, or other psychotic disorders

          -  Psychiatric disorder due to a general medical condition

          -  Current substance abuse or dependence

          -  Acute suicide or homicide risk

          -  Unstable or life-threatening medical condition

          -  Primary diagnosis of borderline personality disorder, major depressive disorder, or
             major depression, melancholic subtype

          -  Diagnosis of antisocial personality disorder

          -  At least partial benefit from current treatment regimen

          -  Unwillingness to discontinue current ineffective psycho- or pharmacotherapy

          -  Inability to speak or read English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C. Markowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institution</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.columbiatrauma.org/</url>
    <description>Click here for more information on trauma and PTSD at the Web site of Columbia University Medical Center, New York State Psychiatric Institute</description>
  </link>
  <reference>
    <citation>Bleiberg KL, Markowitz JC. A pilot study of interpersonal psychotherapy for posttraumatic stress disorder. Am J Psychiatry. 2005 Jan;162(1):181-3.</citation>
    <PMID>15625219</PMID>
  </reference>
  <reference>
    <citation>Markowitz JC, Bleiberg KL, Christos P, Levitan E. Solving interpersonal problems correlates with symptom improvement in interpersonal psychotherapy: preliminary findings. J Nerv Ment Dis. 2006 Jan;194(1):15-20.</citation>
    <PMID>16462550</PMID>
  </reference>
  <reference>
    <citation>Taylor S, Thordarson DS, Maxfield L, Fedoroff IC, Lovell K, Ogrodniczuk J. Comparative efficacy, speed, and adverse effects of three PTSD treatments: exposure therapy, EMDR, and relaxation training. J Consult Clin Psychol. 2003 Apr;71(2):330-8.</citation>
    <PMID>12699027</PMID>
  </reference>
  <reference>
    <citation>Markowitz JC, Milrod B, Bleiberg K, Marshall RD. Interpersonal factors in understanding and treating posttraumatic stress disorder. J Psychiatr Pract. 2009 Mar;15(2):133-40. doi: 10.1097/01.pra.0000348366.34419.28. Review.</citation>
    <PMID>19339847</PMID>
  </reference>
  <reference>
    <citation>Markowitz JC, Kaplowitz M, Suh EJ, Meehan KB, Neria Y, Jonker H, Rafaeli A, Lovell K. Treating patients who strain the research psychotherapy paradigm. J Nerv Ment Dis. 2012 Jul;200(7):594-7. doi: 10.1097/NMD.0b013e31825bfaf4.</citation>
    <PMID>22759936</PMID>
  </reference>
  <reference>
    <citation>Amsel LV, Hunter N, Kim S, Fodor KE, Markowitz JC. Does a study focused on trauma encourage patients with psychotic symptoms to seek treatment? Psychiatr Serv. 2012 Apr;63(4):386-9. doi: 10.1176/appi.ps.201100251.</citation>
    <PMID>22476306</PMID>
  </reference>
  <reference>
    <citation>Rafaeli AK, Markowitz JC. Interpersonal psychotherapy (IPT) for PTSD: a case study. Am J Psychother. 2011;65(3):205-23.</citation>
    <PMID>22032045</PMID>
  </reference>
  <reference>
    <citation>Markowitz JC, Milrod BL. The importance of responding to negative affect in psychotherapies. Am J Psychiatry. 2011 Feb;168(2):124-8. doi: 10.1176/appi.ajp.2010.10040636.</citation>
    <PMID>21297048</PMID>
  </reference>
  <reference>
    <citation>Markowitz JC. IPT and PTSD. Depress Anxiety. 2010 Oct;27(10):879-81. doi: 10.1002/da.20752.</citation>
    <PMID>20886608</PMID>
  </reference>
  <results_reference>
    <citation>Markowitz JC, Petkova E, Neria Y, Van Meter PE, Zhao Y, Hembree E, Lovell K, Biyanova T, Marshall RD. Is Exposure Necessary? A Randomized Clinical Trial of Interpersonal Psychotherapy for PTSD. Am J Psychiatry. 2015 May;172(5):430-40. doi: 10.1176/appi.ajp.2014.14070908. Epub 2015 Feb 13.</citation>
    <PMID>25677355</PMID>
  </results_reference>
  <results_reference>
    <citation>Markowitz JC, Meehan KB, Petkova E, Zhao Y, Van Meter PE, Neria Y, Pessin H, Nazia Y. Treatment preferences of psychotherapy patients with chronic PTSD. J Clin Psychiatry. 2016 Mar;77(3):363-70. doi: 10.4088/JCP.14m09640.</citation>
    <PMID>26115532</PMID>
  </results_reference>
  <results_reference>
    <citation>Markowitz JC, Petkova E, Biyanova T, Ding K, Suh EJ, Neria Y. EXPLORING PERSONALITY DIAGNOSIS STABILITY FOLLOWING ACUTE PSYCHOTHERAPY FOR CHRONIC POSTTRAUMATIC STRESS DISORDER. Depress Anxiety. 2015 Dec;32(12):919-26. doi: 10.1002/da.22436. Epub 2015 Oct 6.</citation>
    <PMID>26439430</PMID>
  </results_reference>
  <results_reference>
    <citation>Markowitz JC, Neria Y, Lovell K, Van Meter PE, Petkova E. History of sexual trauma moderates psychotherapy outcome for posttraumatic stress disorder. Depress Anxiety. 2017 Aug;34(8):692-700. doi: 10.1002/da.22619. Epub 2017 Apr 4.</citation>
    <PMID>28376282</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <results_first_submitted>September 8, 2015</results_first_submitted>
  <results_first_submitted_qc>October 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2015</results_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Psychotherapy</keyword>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 Interpersonal Psychotherapy (IPT)</title>
          <description>Participants will receive interpersonal psychotherapy.
Interpersonal Psychotherapy: 14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports</description>
        </group>
        <group group_id="P2">
          <title>2 Prolonged Exposure (PE)</title>
          <description>Participants will receive prolonged exposure therapy.
Prolonged Exposure Therapy: Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma</description>
        </group>
        <group group_id="P3">
          <title>3 Relaxation Therapy</title>
          <description>Participants will receive relaxation therapy.
Relaxation Therapy: Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Interpersonal Psychotherapy (IPT)</title>
          <description>Participants will receive interpersonal psychotherapy.
Interpersonal Psychotherapy: 14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports</description>
        </group>
        <group group_id="B2">
          <title>2 Prolonged Exposure (PE)</title>
          <description>Participants will receive prolonged exposure therapy.
Prolonged Exposure Therapy: Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma</description>
        </group>
        <group group_id="B3">
          <title>3 Relaxation Therapy</title>
          <description>Participants will receive relaxation therapy.
Relaxation Therapy: Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.12" spread="11.21"/>
                    <measurement group_id="B2" value="41.76" spread="11.99"/>
                    <measurement group_id="B3" value="40.62" spread="11.48"/>
                    <measurement group_id="B4" value="40.10" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician-Administered PTSD Scale (CAPS)</title>
        <description>Continuous measure scale of PTSD symptoms severity. Generally considered state of the art. Range 0-136 (17 items each rated for frequency and for intensity, each on a 0-4 scale). Scores &gt;50 indicate at least moderately severe PTSD; scores &lt;20 were defined as remission. See Blake DD, Weathers FW, Nagy LM, et al: The development of a clinician-administered PTSD scale. J Trauma Stress 1995; 8:75–90; Weathers FW, Keane TM, Davidson JRT: Clinician-Administered PTSD Scale: a review of the first ten years of research. Depression and Anxiety 2001;13:132-156</description>
        <time_frame>After 14 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Interpersonal Psychotherapy (IPT)</title>
            <description>Participants will receive interpersonal psychotherapy.
Interpersonal Psychotherapy: 14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports</description>
          </group>
          <group group_id="O2">
            <title>2 Prolonged Exposure (PE)</title>
            <description>Participants will receive prolonged exposure therapy.
Prolonged Exposure Therapy: Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma</description>
          </group>
          <group group_id="O3">
            <title>3 Relaxation Therapy</title>
            <description>Participants will receive relaxation therapy.
Relaxation Therapy: Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-Administered PTSD Scale (CAPS)</title>
          <description>Continuous measure scale of PTSD symptoms severity. Generally considered state of the art. Range 0-136 (17 items each rated for frequency and for intensity, each on a 0-4 scale). Scores &gt;50 indicate at least moderately severe PTSD; scores &lt;20 were defined as remission. See Blake DD, Weathers FW, Nagy LM, et al: The development of a clinician-administered PTSD scale. J Trauma Stress 1995; 8:75–90; Weathers FW, Keane TM, Davidson JRT: Clinician-Administered PTSD Scale: a review of the first ten years of research. Depression and Anxiety 2001;13:132-156</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="16.2"/>
                    <measurement group_id="O2" value="72.1" spread="18.2"/>
                    <measurement group_id="O3" value="68.9" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="24.3"/>
                    <measurement group_id="O2" value="37.5" spread="28.8"/>
                    <measurement group_id="O3" value="46.5" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Rating Scale</title>
        <description>Continuous scale to measure depressive symptom severity with a potential range from 0 to 74. Higher scores indicate more severe depressive symptoms. Scores &lt;8 are generally considered not depressed; 8-12 mildly depressed; 13-19 moderately depressed; 20 and greater, severely depressed. Reference: Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;25:56-62</description>
        <time_frame>After 14 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Interpersonal Psychotherapy (IPT)</title>
            <description>Participants will receive interpersonal psychotherapy.
Interpersonal Psychotherapy: 14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports</description>
          </group>
          <group group_id="O2">
            <title>2 Prolonged Exposure (PE)</title>
            <description>Participants will receive prolonged exposure therapy.
Prolonged Exposure Therapy: Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma</description>
          </group>
          <group group_id="O3">
            <title>3 Relaxation Therapy</title>
            <description>Participants will receive relaxation therapy.
Relaxation Therapy: Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale</title>
          <description>Continuous scale to measure depressive symptom severity with a potential range from 0 to 74. Higher scores indicate more severe depressive symptoms. Scores &lt;8 are generally considered not depressed; 8-12 mildly depressed; 13-19 moderately depressed; 20 and greater, severely depressed. Reference: Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;25:56-62</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="6.5"/>
                    <measurement group_id="O2" value="20.2" spread="6.7"/>
                    <measurement group_id="O3" value="21.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="8.8"/>
                    <measurement group_id="O2" value="12.3" spread="8.8"/>
                    <measurement group_id="O3" value="14.8" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks; treatment responders followed to 26 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Interpersonal Psychotherapy (IPT)</title>
          <description>Participants will receive interpersonal psychotherapy.
Interpersonal Psychotherapy: 14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports</description>
        </group>
        <group group_id="E2">
          <title>2 Prolonged Exposure (PE)</title>
          <description>Participants will receive prolonged exposure therapy.
Prolonged Exposure Therapy: Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma</description>
        </group>
        <group group_id="E3">
          <title>3 Relaxation Therapy</title>
          <description>Participants will receive relaxation therapy.
Relaxation Therapy: Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Clinical deterioration/protocol violation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited generalizability of unmedicated sample; incomplete therapist fidelity rating; limited sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John C. Markowitz, M.D.</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646 774-8098</phone>
      <email>jcm42@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

